Anti-oxidant and anti-inflammatory effects of ellagic and punicic acid in an in vitro model of cardiac fibrosis.


Journal

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
ISSN: 1950-6007
Titre abrégé: Biomed Pharmacother
Pays: France
ID NLM: 8213295

Informations de publication

Date de publication:
Jun 2023
Historique:
received: 02 03 2023
revised: 31 03 2023
accepted: 04 04 2023
medline: 3 5 2023
pubmed: 9 4 2023
entrez: 8 4 2023
Statut: ppublish

Résumé

Cardiac fibrosis is a pathological process characterized by an excessive deposition of extracellular matrix (ECM) and an increased production of fibrillar collagen in the cardiac interstitium, mainly caused by the activation of cardiac fibroblasts and their transition into myofibroblasts. Oxidative stress is deeply implicated in the pathogenesis of cardiac fibrosis both directly and via its involvement in the tumor growth factor β1 (TGF-β1) signaling. Ellagic acid (EA) and punicic acid (PA) are the main components of the Punica granatum L (pomegranate) fruit and seed oil respectively, whose antioxidant, anti-inflammatory and anti-fibrotic effects have been previously described. Therefore, the aim of this study was to investigate the effects of EA or PA or EA+PA in an in vitro model of cardiac fibrosis. Immortalized Human Cardiac Fibroblasts (IM-HCF) were stimulated with 10 ng/ml of TGF-β1 for 24 h to induce a fibrotic damage. Cells were then treated with EA (1 µM), PA (1 µM) or EA+PA for additional 24 h. Both EA and PA reduced the pro-fibrotic proteins expressions and the intracellular reactive oxygen species (ROS) accumulation. The anti-oxidant activity was also observed by Nrf2 activation with the consequent TGF-β1-Smad2/3-MMP2/9 and Wnt/β-catenin signaling inhibition, thus reducing collagen production. EA and PA significantly inhibit NF-κB pathway and, consequently, TNF-α, IL-1β and IL-6 levels: the greater effect was observed when EA and PA were used in combination. These results suggest that EA, PA and in particular EA+PA might be effective in reducing fibrosis through their antioxidant and anti-inflammatory properties by the modulation of different molecular pathways.

Identifiants

pubmed: 37030134
pii: S0753-3322(23)00454-7
doi: 10.1016/j.biopha.2023.114666
pii:
doi:

Substances chimiques

Antioxidants 0
punicic acid VFQ03H211O
Transforming Growth Factor beta1 0
Anti-Inflammatory Agents 0
Ellagic Acid 19YRN3ZS9P

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

114666

Informations de copyright

Copyright © 2023 The Authors. Published by Elsevier Masson SAS.. All rights reserved.

Déclaration de conflit d'intérêts

Conflicts of interest statement The authors declare that there are no conflicts of interest.

Auteurs

Federica Mannino (F)

Department of Clinical and Experimental Medicine, University of Messina, Via C. Valeria, 98125 Messina, Italy.

Chiara Imbesi (C)

Department of Clinical and Experimental Medicine, University of Messina, Via C. Valeria, 98125 Messina, Italy.

Alessandra Bitto (A)

Department of Clinical and Experimental Medicine, University of Messina, Via C. Valeria, 98125 Messina, Italy.

Letteria Minutoli (L)

Department of Clinical and Experimental Medicine, University of Messina, Via C. Valeria, 98125 Messina, Italy.

Francesco Squadrito (F)

Department of Clinical and Experimental Medicine, University of Messina, Via C. Valeria, 98125 Messina, Italy.

Tommaso D'Angelo (T)

Department of Biomedical, Dental, Morphological and Functional Imaging Sciences, University of Messina, Via C. Valeria Gazzi, 98125 Messina, Italy.

Christian Booz (C)

Division of Experimental Imaging, Department of Diagnostic and Interventional Radiology, University Hospital Frankfurt, Theodor-Stern-Kai 7, 60590 Frankfurt am Main, Germany.

Giovanni Pallio (G)

Department of Clinical and Experimental Medicine, University of Messina, Via C. Valeria, 98125 Messina, Italy. Electronic address: gpallio@unime.it.

Natasha Irrera (N)

Department of Clinical and Experimental Medicine, University of Messina, Via C. Valeria, 98125 Messina, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH